What compounds target MAP3K11?

BiohacksAI has identified 40 compounds that interact with MAP3K11 (Mitogen-activated protein kinase kinase kinase 11). Top compounds include: foretinib, tozasertib, ruxolitinib, bosutinib, midostaurin. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MAP3K11 (Mitogen-activated protein kinase)?

MAP3K11 is Mitogen-activated protein kinase kinase kinase 11. It is a molecular target for 40 compounds documented in PubMed bioassay data.

MAP3K11

MOLECULAR TARGET

Mitogen-activated protein kinase kinase kinase 11

40 compounds

MAP3K11 (Mitogen-activated protein kinase kinase kinase 11) is targeted by 40 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAP3K11

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	foretinib	4.34	76
2	tozasertib	4.33	75
3	ruxolitinib	4.23	68
4	bosutinib	4.08	58
5	midostaurin	3.85	46
6	silmitasertib	3.78	43
7	pazopanib	3.69	39
8	neratinib	3.66	38
9	nintedanib	3.61	36
10	tae 684	3.43	30
11	fedratinib	3.40	29
12	gilteritinib	3.40	29
13	dabrafenib	3.30	26
14	dovitinib	3.09	21
15	at 9283	3.09	21
16	lestaurtinib	3.04	20
17	adavosertib	3.04	20
18	pf 03758309	3.00	19
19	orantinib	2.89	17
20	r 406	2.83	16
21	k 252a	2.83	16
22	milciclib	2.77	15
23	pf 00562271	2.77	15
24	capivasertib	2.77	15
25	staurosporinone	2.77	15
26	crenolanib	2.71	14
27	kw 2449	2.64	13
28	ast 487	2.56	12
29	raf 265	2.48	11
30	defactinib	2.48	11
31	azd 7762	2.30	9
32	su 014813	2.20	8
33	rebastinib	2.20	8
34	gsk 1070916	2.20	8
35	encorafenib	2.20	8
36	cyc 116	2.08	7
37	fostamatinib	2.08	7
38	cep 1347	2.08	7
39	pf 03814735	1.79	5
40	ucn 01	1.79	5

About MAP3K11 as a Drug Target

MAP3K11 (Mitogen-activated protein kinase kinase kinase 11) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 40 compounds with documented MAP3K11 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAP3K11 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.